Affiliation: Harvard University
- Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast CancerNadine Tung
Nadine Tung, Beth Israel Deaconess Medical Center Nancy U Lin, Eric P Winer, and Judy E Garber, Dana Farber Cancer Institute Nadine Tung, Nancy U Lin, Eric P Winer, and Judy E Garber, Harvard Medical School, Boston, MA and John Kidd, Brian A Allen, Nanda Singh, Richard J Wenstrup, and Anne Renee Hartman, Myriad Genetic Laboratories, Inc, Salt Lake City, UT
J Clin Oncol 34:1460-8. 2016....
- Outcome of triple negative breast cancer: comparison of sporadic and BRCA1-associated cancersNadine Tung
Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA, 02215, USA
Breast Cancer Res Treat 146:175-82. 2014..Carriers who underwent oophorectomy had a significantly lower rate of breast cancer-related death; this finding should be studied further in all women with TNBC. ..
- What is the optimal endocrine therapy for postmenopausal women with hormone receptor-positive early breast cancer?Nadine Tung
Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, MA 02215, USA
J Clin Oncol 31:1391-7. 2013..She exercises regularly and takes a calcium supplement with vitamin D. Bone density study performed 6 months earlier was normal other than mild osteopenia in the femoral neck (T score, -1.3). Radiation therapy is planned...
- Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor inhibition prevents estrogen receptor-negative cancers in BRCA1-mutant miceLaura N Burga
Division of Hematology Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston MA 02215, USA
Breast Cancer Res 13:R30. 2011..Here we examine the role of EGFR in mammary epithelial cells (MECs) in the emergence of BRCA1-related tumors and as a potential target for the prevention of TNBC...
- Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriersEitan Friedman
The Suzanne Levy Gertner Oncogenetics Unit, The Chaim Sheba Medical Center, Tel Hashomer, Israel, and the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
Breast Cancer Res 8:R15. 2006....
- Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriersSusan L Neuhausen
Department of Epidemiology, University of California Irvine, 224 Irvine Hall, Irvine, CA 92697, USA
Breast Cancer Res 11:R76. 2009..In this study, we investigate the association of variants in genes involved in IGF signaling and risk of breast cancer in women who carry deleterious BRCA1 and BRCA2 mutations...
- Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancersNadine Tung
Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
Breast Cancer Res 12:R95. 2010....
- Management of women with BRCA mutations: a 41-year-old woman with a BRCA mutation and a recent history of breast cancerNadine Tung
Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, MA 02215, USA
JAMA 305:2211-20. 2011..The technology of preimplantation genetic diagnosis and genetic testing in relatives of mutation carriers is discussed...
- Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic featuresNadine Tung
Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Brookline Avenue, Boston, MA 02215, USA
Breast Cancer Res 12:R12. 2010..We undertook a study to assess the clinical factors that predict for an estrogen receptor positive (ER+) breast cancer in BRCA1 mutation carriers and to characterize the pathologic features of these tumors...
- Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriersLarissa J Lee
Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, Massachusetts, USA
Cancer 117:3093-100. 2011..The clinical outcome of women with and without BRCA1 mutations who had TN breast cancer treated with conventional chemotherapy were compared...
- Clinical characteristics and outcomes of BRCA-associated ovarian cancer: genotype and survivalJoyce Liu
Department of Medical Oncology, Dana Farber Partners CancerCare, Boston, MA, USA
Cancer Genet 205:34-41. 2012..This may reflect important differences between BRCA genotypes and should be validated in larger studies...
- Young adult daughters of BRCA1/2 positive mothers: what do they know about hereditary cancer and how much do they worry?ANDREA F PATENAUDE
Dana Farber Cancer Institute, Boston, MA 02215, USA
Psychooncology 22:2024-31. 2013....
- Does neoadjuvant bevacizumab increase surgical complications in breast surgery?M Golshan
Department of Surgery, Brigham and Women s Hospital, Boston, MA, USA
Ann Surg Oncol 18:733-7. 2011..There are limited data on the safety of bevacizumab (bev) in the neoadjuvant setting. We sought to explore the safety of neoadjuvant cisplatin/bev in a protocol for triple negative breast cancer (TNBC)...
- Genetic predisposition directs breast cancer phenotype by dictating progenitor cell fateTheresa A Proia
Department of Anatomy and Cellular Biology, Sackler School of Biomedical Research, Tufts University School of Medicine, 136 Harrison Ave, Boston, MA 02111, USA
Cell Stem Cell 8:149-63. 2011..These findings demonstrate that the genetic background of patient populations, in addition to affecting incidence rates, significantly impacts progenitor cell fate commitment and, therefore, tumor phenotype...
- Counselling framework for moderate-penetrance cancer-susceptibility mutationsNadine Tung
Division of Hematology Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, Massachusetts 02215, USA
Nat Rev Clin Oncol 13:581-8. 2016....
- Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panelNadine Tung
Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts Department of Medicine, Harvard Medical School, Boston, Massachusetts
Cancer 121:25-33. 2015....
- Wild-type BRCA1, but not mutated BRCA1, regulates the expression of the nuclear form of beta-cateninHuchun Li
Division of Experimental Medicine, Beth Israel Deaconess Medical Center, Harvard Institutes of Medicine, 99 Brookline Avenue, RN 330C, Boston, MA 02115, USA
Mol Cancer Res 8:407-20. 2010..This study provides evidence of a novel interaction between BRCA1 and beta-catenin, and that loss of BRCA1 leads to impaired expression of the nuclear form of beta-catenin, which may contribute to the pathogenesis of breast cancer...